<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-11-37-b</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-11-5-9</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Seizure Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Carbamazepine-Induced Motor Impairments</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>05</month>
<year>1997</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>05</month>
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>5</issue>
<fpage>37</fpage>
<lpage>38</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 1997 The Author(s)</copyright-statement>
<copyright-year>1997</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1111/j.1651-2227.1997.tb09025.x" vol="86" page="372">
<article-title>Motor impairments in children with epilepsy treated with carbamazepine</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>Treatment with carbamazepine (CBZ) in therapeutic levels was associated with motor impairments in 19 children with epilepsy, studied during and 6 months after treatment was withdrawn at Huddinge University Hospital, Sweden.</p>
</abstract>
<kwd-group>
<kwd>Carbamazepine</kwd>
<kwd>Motor Impairment</kwd>
<kwd>Chronic Focal Epilepsy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Treatment with carbamazepine (CBZ) in therapeutic levels was associated with motor impairments in 19 children with epilepsy, studied during and 6 months after treatment was withdrawn at Huddinge University Hospital, Sweden. On a Bruininks-Oseretsky standardized test of gross and fine-motor proficiency, the drug-free evaluation showed significant improvements in response speed, fine-motor function, and total test battery scores. In another group of 12 children tested during treatment with CBZ, visual-motor control was impaired on the second test at a 6 month interval. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<p>COMMENT. Fine motor coordination impairments in children with epilepsy treated with carbamazepine may be explained by effects of the antiepileptic drug.</p>
<p><bold>Cerebellar adverse effects of carbamazepine</bold> are reported in 9 (35%) of 26 young adults with chronic focal epilepsy treated at the Klinik Mara 1, Epilepsie-Zentrum Bethel, Bielefeld, Germany [<xref ref-type="bibr" rid="CIT0002">2</xref>]. Serum concentrations of CBZ at onset of ataxic side-effects were related to occurrence of cerebellar atrophy on MRI. Patients showing cerebellar atrophy developed ataxia, nystagmus, and dizziness at lower CBZ levels than those without cerebellar atrophy.</p>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braathen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>von Bahr</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Theorell</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Motor impairments in children with epilepsy treated with carbamazepine</article-title>
<source>Acta Paediatr</source>
<year>1997</year>
<month>Apr</month>
<volume>86</volume>
<issue>4</issue>
<fpage>372</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.1111/j.1651-2227.1997.tb09025.x</pub-id>
<pub-id pub-id-type="pmid">9174222</pub-id>
</element-citation>
</ref>
<ref id="CIT0002">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Specht</surname>
<given-names>U</given-names>
</name>
<name>
<surname>May</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Rohde</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Schutz</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy</article-title>
<source>Arch Neurol</source>
<year>1997</year>
<month>Apr</month>
<volume>54</volume>
<issue>4</issue>
<fpage>427</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.1997.00550160063017</pub-id>
<pub-id pub-id-type="pmid">9109744</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>